Access count of this item: 136

Files in This Item:
File Description SizeFormat 
37_341.pdf265.69 kBAdobe PDFView/Open
Title: Serum gamma-seminoprotein determination in prostatic cancer
Other Titles: 前立腺癌における血清γ-セミノプロティンの測定
Authors: Shimazaki, Jun
Akimoto, Susumu
Akakura, Koichiro
Yoshiki, Tatsuhiro
Yoshida, Osamu
Okada, Kenichiro
Matsuoka, Kei
Noda, Shinshi
Eto, Kosaku
Author's alias: 島崎, 淳
秋元, 晋
赤倉, 功一郎
吉貴, 達寛
吉田, 修
岡田, 謙一郎
松岡, 啓
野田, 進士
江藤, 耕作
Keywords: γ-seminoprotein
Prostatic acid phosphatase
Prostatic cancer
Benign prostatic hypertrophy
Issue Date: Apr-1991
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 37
Issue: 4
Start page: 341
End page: 347
Abstract: 前立腺癌の新しいマーカーとして,γ-セミノプロテイン(γ-Sm)と前立腺性酸性ホスファターゼ(PAP)とを比較評価した.未治療前立腺癌におけるγ-SMおよびPAPのsensitivityは,それぞれ81%,67%であった.γ-Smはすべての病期で前立腺肥大症と比較して陽性率が高かった.前立腺癌ではγ-SmとPAPは相関を示さなかった.γ-SmとPAPを同時に測定することにより,感度が上昇した.γ-SmおよびPAPのspecificityはそれぞれ87%と90%であった.内分泌療法を施行した病期D2において,γ-SmはPAPよりもより多く正常化した.以上より,γ-Smは前立腺癌のもう1つの有用なマーカーであるといえる
Serum gamma-seminoprotein (gamma-Sm) was evaluated as a new marker for prostatic cancer in comparison with prostatic acid phosphatase (PAP). The sensitivity of gamma-Sm and PAP for untreated prostatic cancer was 81% and 67%, respectively. gamma-Sm showed a higher positive rate over all stages than in benign prostatic hypertrophy (BPH). There was no correlation between gamma-Sm and PAP in prostatic cancer. Improved sensitivity was obtained by simultaneous measurement of gamma-Sm and PAP. Specificity of gamma-Sm and PAP for BPH was 87% and 90%, respectively. gamma-Sm normalized after endocrine therapy for stage D2 more often than did PAP. These results indicate that gamma-Sm is another useful marker to evaluate prostatic cancer.
PubMed ID: 1716404
Appears in Collections:Vol.37 No.4

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.